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Introduction 
Most  of  the  drugs  form  a  drug-protein  complex  with 
plasma proteins like albumin, alpha-1-acid glycoproteins, 
lipoproteins. Plasma protein binding of a drug is one of the 
determinants  of  drug’s  pharmacokinetic  parameters. 
Serum albumin is produced by the lliver, with a molecular 
weight  of  65000  –  69000  Da.  This  protein  serves  as  a 
depot and transport protein for numerous endogenous and 
exogenous compounds, which plays an important role in 
binding  phenomenon.
1  Albumin  has  the  ability  to  bind 
reversibly  with  different  kind  of  ligands.  These  ligands 
represent  a  spectrum  of  chemically  diverse  molecules, 
including  fatty  acids,  amino  acids  (tryptophan  and 
cysteine),  steroids,  metals  such  as  calcium,  copper  and 
zinc, and numerous pharmaceuticals.
2,3 
Human  serum  albumin  (HAS)  has  three  highly  specific 
binding sites. These sites are called the warfarin/ranitidine, 
the benzodiazepine and the digoxin binding sites, and are 
also denoted as site-1, site-2 and site-3 respectively.
4,5 Free 
fatty  acids  are  highly  protein  bound  and  replace  many 
drugs and other ligands from its binding site on albumin.
6,7 
Metoprolol succinate is a cardioselective β-blocker used in 
the management of hypertension, angina pectoris, cardiac 
arrhythmias, myocardial infarction and heart failure.
8 Due 
to  its  selective  ß1  receptor  blocking  property  it  is  also 
prescribed in performance anxiety, social anxiety disorder 
and  other  anxiety  disorders.  A  study  has  shown  that 
metoprolol  succinate  is  highly  protein  bound  and 
suprapharmacologic  concentration  of  NSAIDs  increases 
the  free  fraction  of  this  drug.
9  However  until  now,  no 
report has been published  about the interference of  free 
plasma  fatty  acid  in  binding  profile  of  metoprolol 
succinate. The concentration of free fatty acid in blood is 
increased by the intake of fatty diet. Since free fatty acid is 
highly  protein  bound,  therefore,  we  hypothesized  that 
dietary  fat  originates  free  fatty  acid  may  displace  the 
bound metoprolol succinate from its albumin binding site 
and also may interfere with the pharmacokinetic property 
of  metoprolol  succinate.  Therefore  present  study  was 
undertaken to characterize the binding profile as well as to 
notify  the  interaction  of  palmitic  acid  with  metoprolol 
succinate  at  its  binding  site  on  albumin  using  bovine 
serum albumin employing equilibrium dialysis method. 
 
Materials and Methods 
Materials and instruments 
Dialysis  membrane  (molecular  weight  cut  off  at  3500 
Daltons) was purchased from Medicell International Ltd., 
UK  and  bovine  serum  albumin  (molecular  weight 
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Abstract 
Purpose: The aim of this study was to characterize the binding profile as well as to notify 
the interaction of palmitic acid with metoprolol succinate at its binding site on albumin. 
Methods: The binding of metoprolol succinate to bovine serum albumin (BSA) was studied 
by equilibrium dialysis method (ED) at 27°C and pH 7.4, in order to have an insight in the 
binding chemistry of the drug to BSA in presence and absence of palmitic acid. The study 
was carried out using ranitidine as site-1 and diazepam as site-2 specific probe.  
Results: Different analysis of binding of  metoprolol succinate to  bovine serum  albumin 
suggested two sets of association constants: high affinity association constant (k1 = 11.0 x 
10
5 M
-1) with low capacity (n1 = 2) and low affinity association (k2 = 4.0×10
5 M
-1) constant 
with high capacity (n2 = 8) at pH 7.4 and 27°C. During concurrent administration of palmitic 
acid and metoprolol succinate in presence or absence of ranitidine or diazepam, it was found 
that palmitic acid displaced metoprolol succinate from its binding site on BSA resulting 
reduced  binding  of  metoprolol  succinate  to  BSA.  The  increment  in  free  fraction  of 
metoprolol  succinate  was  from  26.27%  to  55.08%  upon  the  addition  of  increased 
concentration of palmitic acid at a concentration of 0×10
-5 M to 16×10
-5 M. In presence of 
ranitidine and diazepam, palmitic acid further increases the free fraction of metoprolol 
succinate from 33.05% to 66.95% and 40.68% to 72.88%, respectively.  
Conclusion:  This  data  provided  the  evidence  of  interaction  at  higher  concentration  of 
palmitic  acid  at  the  binding  sites  on  BSA,  which  might  change  the  pharmacokinetic 
properties of metoprolol succinate. 
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approximately 66210 Dalton, fatty acid free, fraction V, 
96-98%)  from  Sigma  Chemical  Co.,  USA.  Ranitidine 
hydrochloride, diazepam, metoprolol succinate were gifted 
by Novo Healthcare and Pharma Ltd. (Bangladesh). High-
resolution  UV-VIS  spectrophotomer  (SP8-400  UV/VIS 
Spectrophotometer,  Thermospectronic,  England)  and 
Metabolic  Shaking  Incubator  (Clifton  Shaking  Bath, 
Nickel  Electro  Ltd.,  England)  were  used  in  the 
experiment.  All  other  chemicals  used  in  the  experiment 
were of commercial grade. Dialysis membrane used in the 
experiment was cut into small pieces and was boiled for 8 
hours at 65-70°C in de-ionized water to remove sulfur. 
 
Preparation of standard curve 
For  the  preparation  of  standard  curves  of  ranitidine 
hydrochloride,  diazepam  and  metoprolol  succinate 
solutions of different concentrations (0×10
-5 M to16×10
-5 
M) of these drugs were prepared in phosphate buffer of pH 
7.4 and absorbance values were taken at λmax 318 nm, 235 
nm  and  222  nm  respectively.  Standard  curves  were 
obtained  by  plotting  the  absorbance  values  against  the 
corresponding concentrations. 
 
Estimation of association constant  
To  determine  the  association  constant  of  metoprolol 
succinate, different  concentrations  (2×10
-5  M  to  20×10
-5 
M)  of  metoprolol  succinate  solutions  were  mixed  with 
prepared BSA solution (2×10
-5 M in phosphate buffered 
saline, pH 7.4) to get a final volume of 5 ml each. These 
solutions  were  allowed  to  stand  for  10  minutes  for  the 
maximum binding of metoprolol succinate to BSA. From 
each  mixture,  3.5  ml  of  solution  was  withdrawn  and 
poured  into  previously  prepared  semi-permeable 
membrane tubes and both sides of the membranes were 
sealed  properly.  The  membrane  tubes  containing  drug-
protein  mixture  were  immersed  in  conical  flasks 
containing 30 ml of 0.067 M phosphate buffer solution(pH 
7.4).  All  the  conical  flasks  were  placed  in  a  metabolic 
shaker for dialysis for 12 hours at 27°C in 20 rpm. This 
temperature was selected due to get higher binding affinity 
with BSA of drug.
10 Buffer samples were collected from 
each  conical  flask  after  dialysis  and  free  fraction  of 
metoprolol  succinate  was  measured  by  UV 
spectrophotometer (λmax 222 nm).
10 
 
Determination  of  binding  site  of  metoprolol  using 
ranitidine hydrochloride as site-1 specific probe 
To determine the binding sites of metoprolol succinate at 
BSA,  the  concentrations  of  BSA  and  probe  (ranitidine 
hydrochloride  as  site-1  specific  probe)  were  remained 
fixed  in  1:1  ratio  (2×10
-5  M:  2×10
-5  M)  and  the 
concentration  of  metoprolol  succinate  was  added  in 
increased  concentration  (0  to  20×10
-5  M).  So,  the  final 
ratio  of  BSA:  Probe:  Metoprolol  succinate  were  1:1:0, 
1:1:2, 1:1:4, 1:1: 6, 1:1:8, 1:1:10. The dialysis was carried 
out as described above and free concentration of ranitidine 
hydrochloride was measured at λmax 318 nm. Only BSA 
solution  and  mixture  of  BSA  and  metoprolol  succinate 
were  used  as  positive  and  negative  control  during  the 
measurement.
10 
 
Determination  of  binding  site  of  metoprolol  succinate 
using diazepam as site-2 specific probe 
To determine the binding sites of metoprolol succinate at 
BSA, the concentrations of BSA and probe (diazepam as 
site-2  specific  probe)  were  remained  fixed  in  1:1  ratio 
(2×10
-5 M: 2×10
-5 M) and the concentration of metoprolol 
succinate  was  added  in  increased  concentration  (0  to 
20×10
-5 M). So, the final ratio of BSA: Probe: Metoprolol 
succinate were 1:1:0, 1:1:2, 1:1:4, 1:1:6, 1:1:8, 1:1:10. The 
dialysis  was  carried  out  as  described  above  and  free 
concentration of diazepam was measured at λmax 235 nm. 
Only BSA solution and mixture of BSA and metoprolol 
succinate  were  used  as  positive  and  negative  control 
during the measurement.
10 
 
Effect of palmitic acid on metoprolol succinate binding 
to BSA 
The effect of palmitic acid on metoprolol succinate, when 
bound to BSA was estimated in absence and in presence 
of site specific probes (using ranitidine hydrochloride as 
site-1 specific and diazepam as site-2 specific probes). In 
absence of site specific probes, the BSA and metoprolol 
succinate was mixed at 1:1 ratio (2×10
-5 M: 2×10
-5 M) and 
then palmitic acid was added in increasing concentration 
(0 to 20×10
-5 M) to make final ratio of BSA, metoprolol 
succinate and palmitic acid in each experiment as 1:1:0, 
1:1:1, 1:1:2, 1:1:4, 1:1:6, 1:1:8, 1:1:10. While in presence 
of  probes;  BSA,  probe  and  metoprolol  succinate  were 
mixed  at  ratio  of  1:2:1  and  palmitic  acid  was  added  in 
increasing concentration to make the final ratio of BSA, 
probe, metoprolol succinate and palmitic acid as 1:2:1:0, 
1:2:1:1, 1:2:1:2, 1:2:1:4, 1:2:1:6, 1:2:1:8, 1:2:1:10 in each 
analysis. Dialysis was carried out and the amount of free 
metoprolol  succinate  was  measured  in  absence  and  in 
presence  of  probes  as  described  above.  Only  BSA  was 
used  as  positive  control,  mixture  of  BSA  and  palmitic 
acid, and mixture of BSA, palmitic acid and probe were 
used as negative control.
10 
 
Results and Discussion 
Estimation of binding parameters 
The binding parameters of metoprolol succinate have been 
characterized  using  Scatchard  type  of  analyses  of  the 
binding of drug to albumin (Figure 1). Scatchard analysis 
of the binding of the drug at pH 7.4 and at 27°C provided 
a non-liner curve, suggesting the presence of at least two 
classes  of  binding  sites  for  the  binding  of  metoprolol 
succinate to BSA. As shown in Table 1, the number of 
high affinity binding site (n1) for metoprolol succinate was 
approximately 2.1 (low capacity) and the number of low 
affinity  binding  site  (n2)  was  approximately  8  (high 
capacity). The  high affinity  association constant  (k1)  for 
the metoprolol succinate binding to BSA at pH 7.4 is quite 
high  (11.2×10
5  M
-1),  while  the  low  affinity  association 
constant (k2) for this drug to BSA is about 3 fold lower 
(4×10
5  M
-1)  than  that  of  primary  association  constant.  
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These  findings  indicate  that  metoprolol  succinate  is 
significantly bound to BSA.  
 
 
Figure 1. Scatchard plot for the binding of metoprolol succinate 
to BSA at pH 7.4 and 27°C. Metoprolol Succinate [0×10
-5 M to 
20×10
-5  M]  was  added  to  BSA  [2×10
-5  M]  and  dialyzed  as 
described  under  materials  and  methods.  Free  fraction  of 
metoprolol  was  measured  by  UV-spectroscopic  method  and 
analyzed. r, the ratio of the molar concentration of bound drug to 
the molar concentration of protein; Df, molar concentration of free 
drug. 
 
Table 1. Association constant of metoprolol succinate bound to 
BSA at pH 7.4 (27°C) 
pH 
Association constant 
k1(n1=2.1±0.1)(high affinity)  k2(n2=8.0±0.1)(low affinity) 
7.4  11.0 ± 0.07  4.0 ± 0.03 
Value  represents  the  mean  ±  SEM  of  three  independent 
experiments 
 
Interaction  of  metoprolol  succinate  with  site  specific 
probes 
The effects of metoprolol succinate on the binding of site 
specific  probes  were  examined  to  determine  whether 
metoprolol succinate binds preferentially with site-1 or 
site-2  on  BSA.  As  mentioned  under  materials  and 
methods, site specific probe and BSA were mixed at 1:1 
molar  ratio  and  metoprolol  succinate  was  added  in  an 
increased  concentration  from  0×10
-5  M  to  16×10
-5  M. 
The  result  showed  that  metoprolol  succinate  increased 
the  free  fraction  of  ranitidine  hydrochloride  and 
diazepam from 18.13% to 22.5% and 19.73% to 44.58%, 
respectively (Figure 2).  
 
 
Figure 2. Free fraction of ranitidine or diazepam bound to BSA 
(1:1)  upon  the  addition  of  metoprolol  succinate.  The 
concentrations  used  in  the  binding  study  were:  [BSA]  = 
[ranitidine]  =  2×10
-5  M;  [BSA]  =  [diazepam]  =  2×10
-5  M;  and 
[metoprolol succinate] = 2-20×10
-5 M. 
Interaction of palmitic acid with site specific probes 
The  effect  of  palmitic  acid  was  measured  to  know 
whether it can release the ranitidine and diazepam from 
their binding sites or not. It was found that palmitic acid 
at a concentration of 0×10
-5 M to 16×10
-5 M increased 
the free fraction  ranitidine from  16.0 to  39.8% and  of 
diazepam from 11.5% to 58.7% (Figure 3). 
 
 
Figure 3. Free fraction of ranitidine () or diazepam () bound 
to BSA (1:1) upon the addition of palmitic acid at 27°C and pH 
7.4. The concentrations used in the binding study were: [BSA] = 
[ranitidine]  =  2×10
-5  M;  [BSA]  =  [diazepam]  =  2×10
-5  M;  and 
[Metoprolol] = 0-16×10
-5 M. 
 
Interaction of palmitic acid with metoprolol succinate 
at the binding sites on BSA  
The interactions at bindings sites on BSA were measured 
between  metoprolol  succinate  and  palmtic  acid  in  the 
absence or in presence of site specific probes ranitidine 
and diazepam, respectively. In absence of both ranitidine 
and diazepam, palmitic acid increased the free fraction of 
metoprolol succinate from 26.27% to 55.08% with  the 
addition of palmitic acid from 0×10
-5 M to 16×10
-5 M 
(Figure  4).  Whereas,  in  presence  of  ranitidine  and 
diazepam,  palmitic  acid  at  the  same  concentration, 
increased the free fraction of metoprolol succinate from 
33.05% to 66.95% and 40.68% to 72.88%, respectively. 
 
Figure 4. Free fraction of metoprolol succinate in the absence or 
presence of probes to BSA at 2:1 molar ratio upon the addition 
of palmitic acid at 27°C and pH 7.4. The molar concentrations 
used  in  the  binding  study  were:  [BSA]:  [probe]:  [metoprolol 
succinate] = 1:2:1; and [palmitic acid] = 0-16×10
-5 M.  
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Binding of drugs are determined by studying its ability to 
displace  the  site  specific  probes.  The  association 
constants as shown in Table 1 indicate that metoprolol 
succinate is highly bound to BSA. Figure 2 shows the 
change in free concentration of ranitidine and diazepam 
by  metoprolol  succinate.  It  is  seen  that  the  free 
concentration of ranitidine hydrochloride increased from 
18.13%  to  22.50%,  whereas,  the  free  concentration  of 
diazepam was increased from 19.73% to 44.58% by the 
same  drug.  From  this  observation  it  can  be  said  that 
metoprolol  succinate  at  higher  concentration  displaced 
diazepam to a greater extent as compared to ranitidine, 
so  metoprolol  succinate  has  greater  affinity  for  site-2 
than for site-1 on the BSA molecule. This implies that at 
a lower drug to BSA ratio, metoprolol succinate binds to 
its high affinity site i.e., site-2 or the benzodiazepine site, 
whereas  at  higher  ratio  it  not  only  binds  to  its  high 
affinity site but also to its low affinity site i.e., site-1 or 
the warfarin/ranitidine site on the BSA molecule. 
The pharmacokinetic properties of drugs are influenced 
by  exogenous  as  well  as  endogenous  compounds  by 
binding  to  serum  albumin  in  a  reversible  manner. 
Regular diet contains various fats and fatty acids. These 
fatty acids are highly protein bound and displaces drugs 
and other endogenous molecules from their binding sites 
on  albumin.
7-9  Plasma  protein  binding  properties  are 
considered  to  be  the  primary  determinants  of  the 
pharmacokinetic  properties  of  many  drugs.  Therefore 
any alteration or change in the serum albumin binding of 
these  drugs  might  lead  to  a  change  in  the 
pharmacokinetic  properties  of  these  drugs.  Figure  4 
showed  the  change  in  the  free  concentration  of 
metoprolol succinate bound to BSA in the presence of 
palmitic  acid  at  pH  7.4  and  at  27ºC.  As  observed  in 
Figure 4, the free fraction of metoprolol succinate was 
increased from 26.27% to 55.08% by palmitic acid in the 
absence of probes. Whereas in the presence of ranitidine, 
this increment was from 33.05% to 66.95%. While site-2 
was blocked by sufficient amount of diazepam, palmitic 
acid increased the free fraction of metoprolol succinate 
from  40.68%  to  72.88%  as  shown  in  Figure  4.  These 
findings do not contradict with the number of high and 
low  affinity  binding  sites  of  metoprolol  succinate  on 
BSA.  This  suggests  that  metoprolol  succinate  is 
displaced  to  a  greater  extent  by  palmitic  acid  in  the 
presence of diazepam compared to ranitidine. We found 
that  palmitic  acid,  a  saturated  fatty  acid,  displaces 
metoprolol from  its  binding  sites on  BSA.  As  there  is 
strong  analogy  between  BSA  and  HSA,  it  is  assumed 
that  similar  types  of  binding  characteristics  will  be 
exhibited by metoprolol succinate when bound to HSA. 
Sometimes  the  pharmacologic  activity  of  a  drug  is 
related to its protein binding. If a drug shows less affinity 
for albumin due to any alteration in protein binding, the 
pharmacologic  effect  of  the  drug  may  be  significantly 
altered.
11-13  Because,  therapeutic  effect  of  a  protein 
bound drug  is related  to its  free drug  concentration  in 
plasma  and  at  the  target  site.
14  But  this  is  not  always 
indicative of its tissue distribution, its elimination or its 
activity. 
 
Conclusion 
In our study, palmitic acid increases the free fraction of 
metoprolol  succinate.  This  probably  enhance  the 
pharmacological  activity  of  metoprolol  succinate. 
Therefore,  precaution  should  be  taken  while  using 
therapeutically. However, the results of the present study 
in combination with the current advances in the binding 
of  metoprolol  succinate  and  interaction  with  fatty  acid 
might be helpful in realizing the overall binding behavior 
of the drug with human serum albumin. Nevertheless, it 
is  too  early  to  draw  such  conclusion  about  the 
pharmacokinetic/pharmacological properties of the drug 
from our limited data. It deserves a more detailed study 
using in vivo experimental model. 
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